Form 4: Nurix Legal Officer Sells NRIX Shares

Nurix Therapeutics' Chief Legal Officer, Christine Ring, sold 14,261 shares of common stock for a weighted average price of $16.6621 per share.

Summary

• Christine Ring, Chief Legal Officer of Nurix Therapeutics, Inc. (NRIX), reported a sale of common stock.
• The transaction involved the disposition of 14,261 shares of NRIX common stock.
• The shares were sold on February 9, 2026, at a weighted average price of $16.6621 per share.
• The sale price ranged from $16.37 to $16.88 per share.
• Following this transaction, Christine Ring beneficially owns 42,749 shares of Nurix Therapeutics common stock.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale can sometimes be seen negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic trading.

Negatives

• An insider sale, even under a 10b5-1 plan, could be perceived as a lack of confidence by some investors, though this is often for personal financial planning.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Nurix Therapeutics' future performance or strategic direction.

Management Comments

• This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
• The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales executed under Rule 10b5-1 plans, are a routine part of executive compensation and personal financial management across the biotechnology industry. These pre-scheduled plans help insiders avoid accusations of trading on material non-public information.

Corporate Governance

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but the 10b5-1 plan suggests a pre-planned liquidity event rather than a reaction to new information.

Key Dates

Keywords

Nurix Therapeutics, NRIX, Christine Ring, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Chief Legal Officer, Equity Transaction